Developing regions vs Luxembourg: Proportion of the target population who received a 3rd dose of
Developing regions
66.0%
in 2024
Luxembourg
97.0%
in 2024
Developing regions rank
12th
Luxembourg rank
11th
Proportion of the target population who received a 3rd dose of over time
- Developing regions
- Luxembourg
How they compare
Luxembourg currently reports 97.0% against 66.0% in Developing regions, a difference of 31.0%.
That makes Luxembourg's figure about 1.5 times Developing regions's.
Across all 17 years both countries report, Luxembourg has been ahead every year.
Developing regions ranks 12th and Luxembourg ranks 11th of 19 groups.
Luxembourg has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Developing regions | Luxembourg | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.5% | 86.0% | 84.5% | Luxembourg |
| 2010s | 28.4% | 93.4% | 65.0% | Luxembourg |
| 2020s | 56.4% | 96.6% | 40.2% | Luxembourg |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Developing regions or Luxembourg?
- Luxembourg, at 97.0% against 66.0% in Developing regions as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Developing regions and Luxembourg?
- 31.0%, with Luxembourg ahead.
- How many years of comparable data are there for Developing regions and Luxembourg?
- 17 years are reported by both, from 2008 to 2024.
- How do Developing regions and Luxembourg rank globally for proportion of the target population who received a 3rd dose of?
- Developing regions ranks 12th and Luxembourg ranks 11th of 19 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.